Patent US4603123A successfully refreshed from Google Patents.
US4603123A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compounds having antiinflammatory activity, obtained by complexation of piroxican with β-cyclodextrin, and pharmaceutical compositions containing them
Assignee: Chiesi Farmaceutici SpA
•
Filing: 1984-11-13
•
Granted: 1986-07-29
•
Expires: 2004-11-13
Abstract
Abstract New inclusion compounds of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dioxide with α, β or γ cyclodextrins, obtained by reaction of said cyclodextrins and said 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dioxide in aqueous or water/organic solutions are described. The ratio between 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-1,1-dioxide and the cyclodextrins is comprised between 1:10 and 1:1; preferably, it is about 1:2.5. The compounds of the invention possess high antiinflammatory and analgesic activities, together with a considerably reduced gastrolesive action.
Inventors
- 👤 Paolo Chiesi
- 👤 Vittorino Servadio
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 17:08
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/54; A61K31/5415; B; B82; B82Y; B82Y5/00; A61K31/70; A61K31/715; A61K31/716; A61K31/724; A61K47/00; A61K47/50; A61K47/69; A61K47/6949; A61K47/6951; A61P; A61P25/00; A61P25/04; A61P29/00; C; C08; C08B; C08B37/00; C08B37/0006; C08B37/0009; C08B37/0012; C08B37/0015
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
23 words
The inclusion complex of piroxicam with α,β- or γ cyclodextrin, in the ratio between 1:1 and 1:10 of piroxicam and said cyclodextrin respectively.
Claim 2
Dependent Claim
23 words
The inclusion complex of piroxicam with α,β- or γ cyclodextrin, in the ratio between 1:1 and 1:10 of piroxicam and said cyclodextrin respectively.
Claim 3
Dependent Claim
13 words
The inclusion complex according to claim 1, wherein the piroxicam/cyclodextrin ratio is 1:2.5.
Claim 4
Dependent Claim
12 words
The inclusion complex according to claim 1, wherein the cyclodextrin is β-cyclodextrin.
Claim 5
Dependent Claim
45 words
A pharmaceutical composition useful as an analgesic, in unit dosage form comprising an effective amount of the inclusion complex of piroxicam and beta-cyclodextrin wherein said piroxicam and said cyclodextrin are in the ratio between 1:1 and 1:10 respectively and at least one pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
45 words
A pharmaceutical composition useful as an analgesic, in unit dosage form comprising an effective amount of the inclusion complex of piroxicam and beta-cyclodextrin wherein said piroxicam and said cyclodextrin are in the ratio between 1:1 and 1:10 respectively and at least one pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
34 words
A pharmaceutical composition according to claim 4 in the form of tablets, compresses, sachets, suppositories, suited for oral or rectal administration, containing from 10 to 50 mgs of said inclusion complex per unit dosage.
Claim 8
Dependent Claim
54 words
A pharmaceutical composition having antiinflammatory activity for oral or rectal administration, in the form of tablets, capsules, sachets or suppositories containing an effective amount of an inclusion complex of piroxicam and beta-cyclodextrin wherein said piroxicam and said cyclodextrin are in the ratio between 1:1 and 1:10 respectively and at least one pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
54 words
A pharmaceutical composition having antiinflammatory activity for oral or rectal administration, in the form of tablets, capsules, sachets or suppositories containing an effective amount of an inclusion complex of piroxicam and beta-cyclodextrin wherein said piroxicam and said cyclodextrin are in the ratio between 1:1 and 1:10 respectively and at least one pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
20 words
A pharmaceutical composition according to claim 6, containing from 10 to 50 mg of said inclusion complex per unit dosage.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-07-28 | 1990-01-27 | 1990-07-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-07-28 | 1994-01-27 | 1994-07-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-07-28 | 1998-01-27 | 1998-07-29 | $7700.00 | Window Closed / Lapsed |